Nikhil Prasad Fact checked by:Thailand Medical News Team Oct 12, 2024 3 days, 12 hours, 22 minutes ago
Medical News: Researchers have found a crucial link between severe COVID-19 infections and the development of acute coronary syndrome (ACS), a condition that includes heart attacks. The study reveals how the inflammatory response caused by COVID-19, especially high levels of interleukin-6 (IL-6), can increase the risk of heart complications. This
Medical News report explores the details of this research and its key findings, shedding light on why some COVID-19 patients develop serious heart conditions.
COVID-19 increases the risk of heart attacks through Interleukin-6
Understanding the Study
The research focused on analyzing the health records of 1,753 COVID-19 patients hospitalized between 2020 and 2022. Out of these, 37 patients developed ACS, and 159 patients were selected as controls for comparison. The researchers looked into several health factors, including IL-6 levels, cardiovascular disease (CVD), diabetes, hypertension, and other laboratory biomarkers to find connections to ACS.
The patients who developed ACS were generally older and had more underlying health conditions such as diabetes, hypertension, and ischemic heart disease. These patients were also more likely to experience severe COVID-19 symptoms, including decreased consciousness, intensive care unit (ICU) admissions, and even higher mortality rates.
The Role of IL-6 and Other Risk Factors
One of the most important findings of the study was that patients with higher baseline levels of IL-6 were more likely to develop ACS. IL-6 is a type of protein produced in response to inflammation, and its levels rise during infections and other inflammatory conditions. In COVID-19 patients, the cytokine storm, a severe immune reaction where the body releases too many cytokines (including IL-6), can cause widespread damage, including harm to the heart.
The researchers used logistic regression models to analyze the data and found that the likelihood of developing ACS was higher for older patients and those with existing heart conditions. The study showed that a one-point increase in IL-6 levels raised the risk of ACS by 44%. Similarly, older age and pre-existing cardiovascular disease increased the risk significantly.
Inflammatory Markers and Heart Complications
In addition to IL-6, other inflammatory markers like D-dimer, which indicates blood clotting, and troponin, a marker of heart injury, were higher in patients who developed ACS. This suggests that inflammation and blood clotting are closely related to heart damage in severe COVID-19 cases.
The study also found that patients with lower levels of red blood cells and hemoglobin were more likely to develop ACS. This points to how COVID-19 may affect the body's ability to carry oxygen, further increasing the risk of heart complications.
The inflammatory response caused by COVID-19 is not only about IL-6. Other proteins, such as C-reactive protein (CRP) and tumor necrosis factor (TNF-α), also contribute to heart damage. H
owever, IL-6 stood out as one of the strongest predictors of ACS development in this study.
Key Findings
-Higher IL-6 levels increase ACS risk: Patients with elevated IL-6 at the time of admission were much more likely to experience heart complications.
-Older age and pre-existing conditions matter: Older patients and those with conditions like hypertension and ischemic heart disease faced a much higher risk of ACS.
-Widespread impact of inflammation: Inflammation was the central factor in driving heart damage in COVID-19 patients, with other markers like D-dimer and troponin playing a role.
-Increased ICU admissions and mortality: ACS patients were far more likely to be admitted to the ICU and had a much higher death rate, with 70% of ACS patients succumbing to their illness compared to less than 1% in the control group.
The Bigger Picture: COVID-19 and Heart Disease
COVID-19 has been linked to many complications, and heart disease is among the most severe. The virus can cause direct harm to the heart through inflammation and clotting, as well as indirectly by exacerbating pre-existing conditions. For people with underlying cardiovascular problems, COVID-19 can be particularly deadly.
The findings of this study highlight the importance of early detection and management of inflammation in COVID-19 patients, especially those with a higher risk of heart disease. Monitoring IL-6 levels could help doctors identify patients who are more likely to develop ACS and other heart complications, allowing them to take preventive measures.
Study Limitations and Future Research
While this study provides valuable insights, there are some limitations. It was conducted at a single hospital, and the sample size of ACS patients was relatively small. Further research is needed to confirm these findings in larger populations and different settings.
Additionally, more studies are required to explore the effectiveness of treatments that target IL-6 and other inflammatory markers in reducing the risk of heart complications in COVID-19 patients. Drugs that lower inflammation, such as IL-6 inhibitors, might offer a way to protect the heart during severe infections.
Conclusion
This research adds to the growing body of evidence that COVID-19 can have serious effects on the heart, particularly through inflammation. Elevated levels of IL-6, older age, and pre-existing cardiovascular conditions significantly increase the risk of developing ACS in COVID-19 patients. As the pandemic continues, understanding these risks is crucial for managing and treating patients effectively.
The study findings were published in the peer-reviewed journal: BMC Cardiovascular Disorders.
https://link.springer.com/article/10.1186/s12872-024-04234-x
For the latest COVID-19 News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/covid-19-can-lead-to-heart-fibrosis
https://www.thailandmedical.news/news/taiwanese-study-reveals-heart-health-benefits-of-the-phytochemical-momordicine-i-from-bitter-melon
Share
Tweet
Share
